Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Akamai, answering, apply, applying, arm, assumed, average, banc, began, benzene, born, Brasil, cartridge, claim, comprised, cumulative, dealt, depict, en, entity, essentially, FASB, formulation, Immunocore, insignificant, Jardiance, judge, lifetime, Limelight, month, notification, officially, partner, preliminarily, preliminary, public, remanding, resubmission, retained, retrospectively, Sawai, showed, standalone, step, supplemental, vacated
Removed:
attributable, duloxetine, emerging, glucose, raloxifene, sodium
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 2 Stock Asset Purchase Agreement Between Novartis Ag and Eli Lilly and Company
- 12 Statement Re: Computation of Ratio of Earnings to Fixed Charges
- 31.1 Rule 13A-14(A) Certification of John C. Lechleiter, Chairman, President, and CEO
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, CFO
- 32 Section 1350 Certification
- Download Excel data file
- View Excel data file
Related press release
LLY similar filings
Filing view
External links
EXHIBIT 12. Statement Re: Computation of Ratio of Earnings to Fixed Charges
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
Six Months Ended June 30, | Years Ended December 31, | |||||||||||||||||||||||
2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||||||||||||||||||
(Dollars in millions) | ||||||||||||||||||||||||
Consolidated pretax income | $ | 1,831.2 | $ | 5,889.3 | $ | 5,408.2 | $ | 5,349.5 | $ | 6,525.2 | $ | 5,357.8 | ||||||||||||
Interest(1) | 89.8 | 184.2 | 198.8 | 211.7 | 211.5 | 291.5 | ||||||||||||||||||
Less interest capitalized during the period | (16.6 | ) | (24.1 | ) | (21.0 | ) | (25.7 | ) | (26.0 | ) | (30.2 | ) | ||||||||||||
Earnings | $ | 1,904.4 | $ | 6,049.4 | $ | 5,586.0 | $ | 5,535.5 | $ | 6,710.7 | $ | 5,619.1 | ||||||||||||
Fixed charges | $ | 89.8 | $ | 184.2 | $ | 198.8 | $ | 211.7 | $ | 211.5 | $ | 291.5 | ||||||||||||
Ratio of earnings to fixed charges | 21.2 | 32.8 | 28.1 | 26.1 | 31.7 | 19.3 |
1 | Interest is based upon interest expense reported as such in the consolidated condensed statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense. |